Holen Sie sich die Stockscreener-App
7.125
12.74%
0.805
Schlusskurs vom Vortag:
$6.32
Offen:
$6.26
24-Stunden-Volumen:
39,484
Relative Volume:
2.28
Marktkapitalisierung:
$99.15M
Einnahmen:
$49.98M
Nettoeinkommen (Verlust:
$-9.64M
KGV:
-10.04
EPS:
-0.71
Netto-Cashflow:
$-4.86M
1W Leistung:
+13.10%
1M Leistung:
+4.01%
6M Leistung:
-15.18%
1J Leistung:
+3.11%
1-Tages-Spanne:
$6.26
$7.5161
1-Wochen-Bereich:
$6.0916
$8.3099
52-Wochen-Spanne:
$5.592
$11.99
Champions Oncology Inc Stock (CSBR) Company Profile
Firmenname
Champions Oncology Inc
Sektor
Branche
Telefon
410-369-0365
Adresse
855 N. WOLFE STREET, BALTIMORE, NJ
Vergleichen Sie CSBR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
7.14 | 87.76M | 49.98M | -9.64M | -4.86M | -0.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.16 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.08 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
848.65 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.12 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
165.08 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-09-12 | Hochstufung | Craig Hallum | Hold → Buy |
| 2019-11-18 | Eingeleitet | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Aktie (CSBR) Neueste Nachrichten
Can Champions Oncology Inc. stock outperform in 2025 bull marketPortfolio Gains Summary & Weekly Sector Rotation Insights - Улправда
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2026 Earnings Call Transcript - Insider Monkey
Champions Oncology Inc Stock Analysis and ForecastSwing Trading Watchlist & Rapid Capital Portfolio - earlytimes.in
Champions Oncology Inc (CSBR) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Champions Oncology earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Champions Oncology signals expanding radiolabeling and data platform as margin improves to 52% - MSN
Earnings call transcript: Champions Oncology Q2 2025 sees strong revenue growth - Investing.com Canada
Champions Oncology Q2 Non-GAAP Earnings Fall, Revenue Rises - marketscreener.com
CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView — Track All Markets
Champions Oncology Reports Record Quarterly Service Revenue - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million - ACCESS Newswire
Champions Oncology (NASDAQ: CSBR) lifts Q2 revenue 11% to $15M, earns profit - Stock Titan
Liquidity Mapping Around (CSBR) Price Events - news.stocktradersdaily.com
First Look: iRobot Bankruptcy, Netflix-WBD Fight, Tesla Robotaxi - GuruFocus
Earnings Scheduled For December 15, 2025 - Benzinga
Dow Settles Lower But Records Weekly Gain: Investor Sentiment Declines, Greed Index Moves To 'Fear' Zone - Benzinga
Argenx, Navan And 3 Stocks To Watch Heading Into Monday - Benzinga
Investors in Champions Oncology (NASDAQ:CSBR) from five years ago are still down 41%, even after 11% gain this past week - simplywall.st
Ocean Power Tech, Champions Oncology set to report earnings Monday By Investing.com - Investing.com Nigeria
Ocean Power Tech, Champions Oncology set to report earnings Monday - Investing.com
Insights Ahead: Champions Oncology's Quarterly Earnings - Benzinga
Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025 - ACCESS Newswire
Shareholders in Champions Oncology (NASDAQ:CSBR) are in the red if they invested five years ago - Yahoo Finance
Will Champions Oncology Inc. (2I3) stock beat value stocks2025 Stock Rankings & Expert Curated Trade Setups - Newser
Will Champions Oncology Inc. stock deliver consistent dividendsJuly 2025 Review & AI Enhanced Trade Execution Alerts - Newser
Will Champions Oncology Inc. (2I3) stock outperform benchmarksInflation Watch & Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH) and Champions Oncology (CSBR) - The Globe and Mail
Why (CSBR) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
Why Champions Oncology Inc. (2I3) stock is a strong buy callWeekly Trade Recap & Breakout Confirmation Alerts - Newser
Will Champions Oncology Inc. stock benefit from infrastructure spending2025 Performance Recap & Step-by-Step Swing Trade Plans - Newser
Why pension funds invest in Champions Oncology Inc. (2I3) stock2025 Top Gainers & Verified Short-Term Trading Plans - Newser
Will Champions Oncology Inc. (2I3) stock deliver stable dividendsJuly 2025 Trends & Weekly Return Optimization Alerts - Newser
What drives Champions Oncology Inc 2I3 stock priceMonthly Performance Summary & Achieve Triple Digit Returns - earlytimes.in
Patient-Derived Xenograft Model Market Size at USD 1.12 Billion in 2031, Forecasted to Grow at 13.4% CAGR Through 2031 | The Insight Partners (PR Newswire) - Aktiellt
Understanding Momentum Shifts in (CSBR) - news.stocktradersdaily.com
Will Champions Oncology Inc. stock outperform Nasdaq indexWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Quantitative breakdown of Champions Oncology Inc. recent move2025 Big Picture & Verified Entry Point Signals - newser.com
What dividend safety rating applies to Champions Oncology Inc. (2I3) stockDip Buying & Free Fast Entry Momentum Trade Alerts - newser.com
How Champions Oncology Inc. (2I3) stock behaves in tightening cycles2025 Pullback Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Candlestick signals on Champions Oncology Inc. stock todayJuly 2025 Levels & Risk Adjusted Swing Trade Ideas - newser.com
Published on: 2025-11-19 21:53:34 - newser.com
How Champions Oncology Inc. (2I3) stock reacts to weak economy - newser.com
Finanzdaten der Champions Oncology Inc-Aktie (CSBR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):